Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684257 | 0.84 | HTR2A (0.56) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL10735669 | 0.84 | HTR2A (0.56) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL10830879 | 0.78 | HTR2A (0.50) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL34463390 | 0.74 | NOTUM (0.56) | HTR2AHTR2CNOTUMHTR1AZAP70 | |
| SCHEMBL7396809 | 0.74 | NOTUM (0.56) | HTR2AHTR2CNOTUMHTR1AZAP70 | |
| SCHEMBL13403405 | 0.74 | NOTUM (0.47) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL235219 | 0.72 | NOTUM (0.59) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL18911623 | 0.72 | HTR2A (0.69) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL6712342 | 0.71 | HTR2A (0.58) | HTR2AHTR2CNOTUMHTR1ASIGMAR1 | |
| SCHEMBL20777927 | 0.70 | PIM1 (0.39) | HTR2AHTR2CNOTUMHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | claimed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | claimed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | claimed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | HTR2A 131/4885HTR2C 484/4885NOTUM 3561/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | HTR2A 259/4885HTR2C 322/4885NOTUM 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.